Edition:
United Kingdom

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

18.92USD
24 Nov 2017
Change (% chg)

$0.78 (+4.30%)
Prev Close
$18.14
Open
$18.20
Day's High
$18.92
Day's Low
$18.14
Volume
112,125
Avg. Vol
54,381
52-wk High
$20.43
52-wk Low
$11.25

Chart for

About

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company... (more)

Overall

Beta: --
Market Cap(Mil.): $1,076.79
Shares Outstanding(Mil.): 57.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.23 16.44
EPS (TTM): -- -- --
ROI: -- 2.53 10.62
ROE: -- 3.17 14.20

BRIEF-Athenex announces Q3 revenue of $14 million

* Says ‍company raises full-year revenue guidance to range of $33 million - $35 million​

09 Nov 2017

BRIEF-Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program

* Athenex announces positive recommendations from the Drug Safety Monitoring Board to continue the oraxol phase iii program

05 Oct 2017

BRIEF-Athenex Inc announces first patient recruitment in phase III clinical trials for KX-01 ointment

* Athenex, Inc. announces first patient recruitment in phase III clinical trials for KX-01 ointment for actinic keratosis

25 Sep 2017

BRIEF-Athenex Inc announces second quarter 2017 results

* Athenex Inc - ‍expect full-year revenues in range of $30 million to $34 million, inclusive of opportunity created by U.S. sodium bicarbonate shortage​ Source text for Eikon: Further company coverage:

14 Aug 2017

BRIEF-Athenex announces approval of tax incentives from State of New York for Dunkirk facility

* Athenex inc - ‍obtained new york state and local tax incentives related to its pharmaceutical manufacturing facility in town of dunkirk, new york​

27 Jul 2017

BRIEF-Athenex reports commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer

* Athenex Inc. announces commencement of patient enrollment for oraxol-plus-ramucirumab phase 1b clinical trial in gastric cancer Source text for Eikon: Further company coverage:

19 Jul 2017

BRIEF-Huateng Ma reports 11.6 pct passive stake in Athenex

* Huateng Ma reports 11.6 percent passive stake in Athenex Inc as of June 14 - SEC filing Source: (http://bit.ly/2ueJu6F) Further company coverage:

13 Jul 2017

BRIEF-Athenex submits IND application of oraxol to Chinese FDA

* Athenex Inc announces submission of investigational new drug application of oraxol to Chinese FDA

05 Jul 2017

BRIEF-Chongqing Lummy Pharma's unit subscribe to s US company Athenex's convertible bonds

* Says U.S. bio pharma company Athenex finished initial public offering

23 Jun 2017

Earnings vs. Estimates